Sharenet Sites 
Sharenet Sites
Broad-Based Black Economic Empowerment Act: Annual Compliance Report
Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or “the Company”)
27 June 2018
BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT
In accordance with the JSE Listings Requirements, applicable to the Company having a secondary
listing on the JSE, notice is hereby given that the Company’s annual compliance report in terms of
section 13G(2) of the South African Broad-Based Black Economic Empowerment Act, 53 of 2003, as
amended, (the “B-BBEE Act”) was submitted to the Broad-Based Black Economic Empowerment
Commission (the “BEE Commission”). The compliance report is available in the governance section
of Mediclinic’s website at www.mediclinic.com.
The compliance report relates to the assessment of the broad-based black economic empowerment
status of Mediclinic Southern Africa (Pty) Ltd, a wholly-owned subsidiary of the Company, in respect of
the Company’s operations in South Africa.
About the B-BBEE Act
The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based
black economic empowerment in South Africa and is intended to encourage transformation by including
black people in the economy. It covers aspects such as ownership, management control, skills
development, enterprise and supplier development and social-economic development. Although
compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary,
an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became
effective in June 2016, to require public companies listed on the JSE to report on their broad-based
black economic empowerment status to the BEE Commission.
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than
700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 27/06/2018 01:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
